Please use this identifier to cite or link to this item:
https://accedacris.ulpgc.es/handle/10553/137691
| Title: | OP37 Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT) | Authors: | Chaparro, M García Donday, M Bode Riestra,Antonio Lucendo, A J Benítez, J M Navarro-Llavat, M Barrio, J Morales-Alvarado, V J Rivero, M Busquets, D Leo Carnerero, E Merino Ochoa, O Nantes Castillejo, O Cabrera Navarro, Pedro Van Domselaar, M Gutiérrez Casbas, A Alonso-Abreu, I Mejuto, R Fernández Salazar, L Iborra, M Martín-Arranz, M D Pineda, J R Sampedro, M J Serra Nilsson, K Bouhmidi Assakali, A Batista, L Muñoz Villafranca, C Rodríguez-Lago, I Ceballos Santos, D S Guerra, I Mañosa, M Marín Jimenez, I Vera Mendoza, I Barreiro-de Acosta, M Domènech, E Esteve, M García-Sánchez, V Nos, P Panés, J Gisbert, J P |
UNESCO Clasification: | 3205 Medicina interna | Issue Date: | 2023 | Publisher: | Oxford University Press | Journal: | Journal of Crohn's and Colitis | Conference: | 18th European Crohn’s and Colitis Organization Inflammatory Bowel Diseases | Abstract: | Comunicación oral al 18º congreso de la European Crohn and Colitis Organization de los resultados del ensayo multicéntrico EXIT | URI: | https://accedacris.ulpgc.es/handle/10553/137691 | ISSN: | 1873-9946 | DOI: | 10.1093/ecco-jcc/jjac190.0037 | Source: | Journal of Crohn's and Colitis [ISSN 1873-9946], v. 17 (S_1), february 2023, pp. i50–i54 |
| Appears in Collections: | Artículos |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.